Understanding the precise role of SRC‐3 in the pathogenesis of ESCC and activation of the IGF/AKT pathway will increase our knowledge of the biologic basis of cancer progression and disruption of functions of SRC‐3 or its target genes and pathways may have potential therapeutic advantages for ESCC. This evidence concerns the gene AKT1 and cancer.